About Agrisoma BioSciences
Agrisoma Biosciences is an agricultural company that has commercialized carinata, a non-food oilseed crop designed for sustainable production of biofuels. Agrisoma sells carinata seed products under the Resonance brand name, and uses advanced crop improvement technologies to provide superior crop varieties to growers.
Expert Collections containing Agrisoma BioSciences
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Agrisoma BioSciences is included in 3 Expert Collections, including Agriculture Technology (Agtech).
Agriculture Technology (Agtech)
Companies in the agtech space, such as equipment manufacturers, surveying drones, geospatial intelligence firms, and farm management platforms
Companies in the Renewable Energy space, including solar, wind, hydro, geothermal, and nuclear energy providers, as well as related software developers.
Game Changers 2018
Agrisoma BioSciences Patents
Agrisoma BioSciences has filed 19 patents.
Brassicaceae, Leaf vegetables, Brassica, Medicinal plants, Vegetable oils
Brassicaceae, Leaf vegetables, Brassica, Medicinal plants, Vegetable oils
Latest Agrisoma BioSciences News
Nov 26, 2019
NuSeed acquires Agrisoma carinata assets In Louisiana, longtime industry executive Glenn Johnston said that NuSeed has acquired the carinata assets of Canadian agricultural pioneer Agrisoma. Johnston was speaking at the IATA Sustainable Aviation Fuels Symposium in New Orleans and confirmed that five Agrisoma staff members have joined NuSeed, with the asset acquisition. Terms of the acquisition have not been disclosed. NuSeed is a subsidiary of the Australian agricultural giant NuFarm, and Johnston indicated that NuSeed will carry forward development and especially deployment of Agrisoma’s carinata seeds to growers in the Americas and internationally. NuSeed focuses on the development and deployment of speciality crops including non gm canola, sorghum, and carinata. “NuSeed has even more capabilities and team members to bring carinata to more growers and increase the acreage,” said Johnston. “It’s very good news for the technology and those who worked at and with Agrisoma to bring the technology forward.” The Agrisoma backstory We reported in March last year that Agrisoma completed a C$12 million investment round . In addition to new investor Desjardins Capital, the lead investor Cycle Capital Management and existing investors BDC Capital and Lune Rouge also participated in the round. Back in 2017, Agrisoma Biosciences closed its $15.4 MM Series B financing round , co-led by new investor Groupe Lune Rouge and current investors Cycle Capital Management, and BDC Venture Capital. And, the company raised $8 million in its Series A investment round in 2014. That round was led by Cycle Capital Management and included participation of BDC Venture Capital. In April 2015, we reported a group led by its management team made an equity investment in the company that gave it a 22 percent stake in the company. The group includes key members of Agrisoma’s senior management, board members and advisors. Carinata: making a move in South America In 2017 we reported that Agrisoma and biorefinery giant UPM signed a long-term supply agreement that will expand the world’s only oilseed crop, developed to produce renewable fuels in South America. Under the deal, the two companies will grow Carinata oilseed crops with third-party farmers in Uruguay and Brazil. Yep, it’s sustainable, and RSB-certified, and off to Europe too Last July, we reported that Agrisoma hired Germany lobbying firm Alber and Geiger to help it get carinata included in the Renewable Energy Directive’s list of approved feedstock , a move that would allow for production across the EU-28 (future EU-27 by the time it’s likely approved). Already they report that the proposal has made it through a first hearing in the European Parliament, promoted by Hungarian and Czech MEPs, with the European Commission and Council currently looking at it. Carinata in flight A second international commercial flight powered by biojet fuel made from Carinata seed oil, the nonstop San Francisco-to-Zurich flight on a Boeing 787 departed Sept. 14 at 2:10 p.m. from San Francisco International Airport and arrived Sept. 15, at 10:10 a.m., at Zurich Airport, making it the longest biojet flight, then, to date. The biojet fuel made from Agrisoma’s Carinata and refined by World Energy’s Paramount facility replaced 30 percent of the petroleum jet fuel needed for the United Airlines flight. While they could have gone higher, 30 percent just worked out to be the number with all the logistics, said Fabijanski. Agrisoma CEO Steve Fabijanski told The Digest in an exclusive interview that these flights are demonstrating that the carinata crop has “legs beyond the diesel market. We’ve done over 20 million liters of diesel fuel, and this shows we can graduate to the jet market as well.” The Multi-Slide Guides Agrisoma Biosciences, Inc. has the world’s largest collection of Carinata and an extensive modern crop improvement program that allows them to select high yielding varieties ideally suited for production across a broad range of geographies. Agrisoma has commercialized Carinata in North and South America, working with hundreds of farmers on over 50,000 acres of production. The production of Agrisoma’s Resonance Carinata is being expanded to multiple locations globally to provide a supply of sustainable, non-food oils for meeting the demand for sustainable biofuels. Resonance Carinata is certified sustainable by the Roundtable on Sustainable Biomaterials (RSB), the global standard and certification scheme for sustainable biofuels. It is one of only four crops in the world to achieve that status. Resonance Carinata meal has recently received regulatory approval as an animal feed, further underscoring the value of this crop to meet the increasing demand for renewable fuel and providing meal for the production of livestock. Additionally, Resonance Carinata is grown on semi-arid farmland, creating new economic and production opportunities for growers. What’s happening with Agrisoma? The Digest’s understanding is that Agrisoma will continue to be active with some contracts the company will continue to manage, after which the Agrisoma board will decide the future direction or any potential operations. The Bottom Line The potential for Resonance Carinata to expand to multiple locations globally to provide a supply of sustainable, non-food oils for meeting the demand for sustainable biofuels — that’s the promise of this move. And, some good news for farmers pursuing off-season cover crops that make money, and potentially for other fuels as well, and for farmers seeking new feed options. There are geographies and times of the year where carinata fits like a glove, and NuSeed is well positioned to build on Agrisoma’s success. Every small company looks for a great exit, and here’s one. Kudos Agrisoma, kudos NuSeed.
Agrisoma BioSciences Frequently Asked Questions (FAQ)
Where is Agrisoma BioSciences's headquarters?
Agrisoma BioSciences's headquarters is located at 200, Rue Montcalm, Gatineau.
What is Agrisoma BioSciences's latest funding round?
Agrisoma BioSciences's latest funding round is Series C.
How much did Agrisoma BioSciences raise?
Agrisoma BioSciences raised a total of $31.71M.
Who are the investors of Agrisoma BioSciences?
Investors of Agrisoma BioSciences include BDC Venture Capital, Cycle Capital, Lune Rouge, Desjardins Capital, Canada-Israel Industrial Research and Development Fund and 3 more.
Who are Agrisoma BioSciences's competitors?
Competitors of Agrisoma BioSciences include Dicerna Pharmaceuticals, Pfenex, Cathay Biotech, Cell Point, Blue Heron Biotech, Agrivida, VirxSys, ZymoGenetics, Chemcel Biotech, Sangamo Therapeutics and 15 more.
Compare Agrisoma BioSciences to Competitors
Ventria Biosciences is a biotechnology company engaged in the development of recombinant proteins using its ExpressTec technology, which achieves yields far greater than those of the next-best plant-based system.
Stine Seed is an independent seed company dedicated to serving farmer customers with support from its team of agronomists and district and regional managers.
Integrated Plant Genetics, Inc. is a development stage biotechnology company, in business to produce and license genes and technologies for the purposes of microbial, horticultural, agricultural and forest tree improvement, including pathogen control. IPG aims to provide contract genetic engineering services, advanced plant breeding technologies for freedom to operate in creating transgenic crops, and assistance in developing regulatory data submission packages. IPG offers environmentally sound and sustainable alternatives to costly and often toxic chemical pest control methods. IPG is a Florida-grown company, with strong ties to the University of Florida, and a commitment to Florida agriculture.
OrphageniX is a drug development company aiming to develop therapeutics for genetic diseases using advancements in "Gene Editing" technologies. OrpageniX will focus on the low volume, high margin specialty pharmaceutical niche area of "Orphan Diseases" which are protected under the Orphan Drug Act (ODA). Per the company, the OrphageniX technology can be used for diagnostics and research tools. Gene Editing uses the cell's innate repair mechanisms to repair mutations that result in genetic diseases. According to OrphaageniX, it is similar to gene therapy but avoids the risks associated with a viral vector. It works like anti-sense and RNAi, but is more efficient and permanent within the repaired cell because it changes the gene itself and not the transient message. The company states that it has major collaborations with Yale Medical School, Albert Einstein Medical Center and the University of Washington.
Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.
Laureate Pharma, Inc. is a full service contract manufacturing organization(CMO) providing development and cGMP manufacturing services in the company's FDA registered facilities in Princeton, New Jersey. The company is dedicated to supporting the development and commercialization of biopharmaceutical, drug and diagnostic products for pharmaceutical, diagnostic and biotech companies.The company aims to provide a range of product development and manufacturing services from cell line optimization and process design to development of full-scale cGMP protein production, purification and aseptic filling, in addition to corresponding testing, validation, analytical and regulatory support. The company's focus is on mammalian cell based monoclonal antibody and recombinant protein production for clinical and modest commercial supply.The company view the company's customers as partners and provide them with flexible solutions that reduce time to clinic and market. Focused on operational excellence, the company's highly experienced staff works with the company's customers to improve the quality of their products and processes.The company value the company's customers, stakeholders and associates. Therefore, the company measure the company's success by meeting the company's customers' needs, generating results in terms of quality, timeliness and on budget performance, as well as fostering an environment of trust, growth and diversity for the company's team.